For more information: www.cdc.gov/COVID19

ACIP COVID-19 Vaccines Work Group

Dr. Beth Bell, Work Group Chair

May 12, 2021
 COVID-19 Vaccine Work Group meets weekly

 Topics covered:

–

–

–

–

Clinical trial data for Pfizer-BioNTech COVID-19 vaccine for adolescents

GRADE/EtR for Pfizer-BioNTech COVID-19 vaccine for adolescents

Clinical considerations for use of COVID-19 vaccines in adolescents

Safety updates

COVID-19 Work Group activities – May 2021

2
 On May 10, 2021, the Food and Drug Administration (FDA) issued an 

Emergency Use Authorization (EUA) for use of the Pfizer-BioNTech

COVID-19 vaccine for the prevention of Coronavirus Disease 2019 

(COVID-19) for individuals 12–15 years of age

Update

3
 Safety, immunogenicity and efficacy of BNT162b2 in persons aged 12-15 years

Dr. John Perez (Pfizer)

 GRADE: Pfizer-BioNTech COVID-19 vaccine

Dr. Megan Wallace (CDC)

 Evidence to Recommendation Framework: Pfizer-BioNTech COVID-19 vaccine in adolescents

Dr. Sara Oliver (CDC)

 Clinical considerations: Adolescent COVID-19 vaccines

Dr. Kate Woodworth(CDC)

 Public Comment

 Discussion 

 VOTE: 

Pfizer-BioNTech COVID-19 vaccine for 12-15 year olds

Today's Agenda

Wednesday, May 12
 Update on thrombosis with thrombocytopenia syndrome (TTS) following Janssen COVID-19 

vaccine

Dr. Tom Shimabukuro (CDC)

 VaST update

Dr. Grace Lee (ACIP, VaST Co-chair)

 COVID-19 vaccine effectiveness studies

Dr. Katherine Fleming-Dutra (CDC)

 Update on emerging SARS-CoV-2 variants and vaccine implications

Dr. Heather Scobie (CDC)

Today's Agenda (continued)

Wednesday, May 12
ACIP members

 Beth Bell (chair)

 Matthew Daley

 Grace Lee

 Jose Romero

 Keipp Talbot

Ex-officio/government members

 FDA: Doran Fink, Rachel Zhang

 NIH: Chris Roberts

 IHS: Thomas Weiser, Uzo Chukwuma

 DOD: Bryan Schumacher

 CMS: Jeff Kelman

 BARDA: Christine Oshansky

 HHS: David Kim

CDC Lead

 Sara Oliver

Work group members

6

Liaisons

 AAFP: Jonathan Temte

 AAP: Sean O’Leary

 ACOG: Denise Jamieson (primary), 

Laura Riley (alternate)

 ACP: Jason Goldman

 AGS: Ken Schmader

 AIM: Rob Shechter (primary), 

Jane Zucker (alternate)

 AMA: Sandra Fryhofer

 ANA: Kendra McMillan (primary), 

Ruth Francis (alternate)

 APhA: Michael Hogue

 ASTHO: Marcus Plescia

 CSTE: Susan Lett (primary), 

Christine Hahn (alternate)

 IDSA: Jeff Duchin (primary), 

Carol Baker (alternate)

Liaisons, cont’d

 NACCHO: Matt Zahn (primary), 

Jeff Duchin (alternate)

 NACI: Matthew Tunis 

 NFID: Bill Schaffner (primary), 

Marla Dalton (alternate)

 NMA: Oliver Brooks

 SHEA: Marci Drees

Consultants

 Ed Belongia 

 Kathy Kinlaw 

 Dayna Matthew 

 Kathleen Neuzil 

 Stanley Perlman 

 Peter Szilagyi
 Amy Blain

 Doug Campos-Outcalt

 Mary Chamberland

 Thomas Clark

 Amanda Cohn

 Jean Cox-Ganser

 Jonathan Duffy

 Kathleen Dooling

 Anthony Fiore

 Mark Freedman

 Julia Gargano

 Sue Gerber

 Jack Gersten

 Susan Goldstein

 Sam Graitcer

CDC participants

7

 Lisa Grohskopf

 Julie Garon

 Stephen Hadler

 Rita Helfand

 Susan Hiers

 Terri Hyde

 Cynthia Jorgensen

 Erin Kennedy

 Sarah Kidd

 Ram Koppaka

 Megan Lindley

 Nicole Lindsey

 Ruth Link-Gelles

 Jessica MacNeil

 Lauri Markowitz

 Natalie Thornburg

 Jennifer Verani

 Megan Wallace

 Annemarie Wasley

 Cindy Weinbaum

 Melinda Wharton

 Yon Yu

 Mona Marin

 Sarah Mbaeyi

 Nancy Messonnier

 Danielle Moulia

 Rebecca Morgan

 Titilope Oduyebo

 Anita Patel

 Janell Routh

 Stephanie Schrag

 Heather Scobie

 Edwin Shanley

 Tom Shimabukuro

 Heidi Soeters

 Mark Sotir

 Stephanie Thomas
For more information, contact CDC

1-800-CDC-INFO (232-4636)

TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the 

official position of the Centers for Disease Control and Prevention.

Thank you!